The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
P53 abnormalities and outcomes in colorectal cancer: a systematic review
Open accessAbstract
We performed a systematic review of studies that investigated the effect of abnormalities of the tumour suppressor gene p53 upon prognosis in patients with colorectal cancer. The methods used to assess p53 status were immunohistochemistry (IHC), indicating abnormal accumulation of p53, and sequence analysis, indicating presence of p53 mutations (mut). We identified 168 reports, with 241 comparisons of relevant end points and survival data on 18 766 patients. We found evidence of both publication bias and heterogeneity of results. Our analysis was hampered by variability in both the assessment of p53 status and the reporting of results. We used a trim and fill method to correct for publication bias and minimised heterogeneity by using well-defined clinical subgroups for the assessment of outcomes. Overall, patients with abnormal p53 were at increased risk of death: relative risk (RR) with IHC 1.32 (95% confidence interval (c.i.) 1.23-1.42) and with mutation analysis 1.31 (95% c.i. 1.19-1.45). The adverse impact of abnormal p53 was greater in patients with lower baseline risk of dying: good prognosis RR (mut) 1.63 (95% c.i. 1.40-1.90) and poor prognosis RR (mut) 1.04 (95% c.i. 0.91-1.19). We found no effect of abnormal p53 on outcome in patients treated with chemotherapy. Abnormal p53 was associated with failure of response to radiotherapy in patients with rectal cancer: RR (mut) 1.49 (95% c.i. 1.25-1.77).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 3×
“Heterogeneity was assessed using the standard approach based on a w(2) distribution for the parameter Q, the measure of heterogeneity in a random effects model (DerSimonian and Laird, 1986).”
MethodInfluentialOperating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907 · cited 1×
“The problems with the design and interpretation of studies dealing with the assessment of prognostic factors have been well rehearsed (Altman and Lyman, 1998; Altman, 2001; Deeks et al, 2003; Riley et al, 2003a, b; Riley et al, 2004).”
BackgroundBond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 2×
“Another complicating factor is that polymorphisms in wild-type p53, and its regulator, MDM2 (Bond et al, 2004), may also affect response to treatment (Sullivan et al, 2004): in this respect, both ‘normal’ and ‘abnormal’ p53 are heterogeneous entities.”
BackgroundEgger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“…of p53, and its abnormalities, on the response of tumours to cytotoxic drugs, radiation, and chemoradiation are complex (Blandino et al, 1999; Bunz et al, 1999; ElDeiry, 2003; Fei and El-Deiry, 2003; Gudkov and Komarova, 2003), and it is, perhaps, unrealistic to expect a straightforward…”
BackgroundSystematic reviews of evaluations of prognostic variables
Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7306.224 · Cited by 756
The role of p53 in determining sensitivity to radiotherapy
Gudkov, A. V., & Komarova, E. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc992 · Cited by 572
Fei, P., & El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206677 · Cited by 498
Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 441
The role of p53 in chemosensitivity and radiosensitivity
El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206949 · Cited by 337
Vogelstein, B. (1990) · Nature · doi:10.1038/348681a0 · Cited by 324
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 313
Methodological challenges in the evaluation of prognostic factors in breast cancer.
Altman, D. G., & Lyman, G. H. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006193704132 · Cited by 271 · cited 1×
“The problems with the design and interpretation of studies dealing with the assessment of prognostic factors have been well rehearsed (Altman and Lyman, 1998; Altman, 2001; Deeks et al, 2003; Riley et al, 2003a, b; Riley et al, 2004).”
BackgroundPolymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo
Sullivan, A., Syed, N., Gasco, M., Bergamaschi, D., Trigiante, G., Attard, M., Hiller, L., Farrell, P. J., Smith, P., Lu, X., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207428 · Cited by 247
The importance of p53 location: nuclear or cytoplasmic zip code?
O’Brate, A., & Giannakakou, P. (2003) · Drug Resistance Updates · doi:10.1016/j.drup.2003.10.004 · Cited by 208
A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma
Riley, R. D., Heney, D., Jones, D. R., Sutton, A. J., Lambert, P. C., Abrams, K. R., Young, B., Wailoo, A. J., & Burchill, S. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1051-2 · Cited by 203
Riley, R. D., Abrams, K. R., Sutton, A. J., Lambert, P. C., Jones, D. R., Heney, D., & Burchill, S. A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600886 · Cited by 166
Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.
Ramos, Y. F., Stad, R. K., Attema, J., Peltenburg, L. T. C., van der Eb, A. J., & Jochemsen, A. G. (2001) · PubMed · Cited by 164
Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Lambert, P. C., Jones, D. R., Sutton, A. J., Young, B., Wailoo, A. J., & Lewis, I. J. (2003) · Health Technology Assessment · doi:10.3310/hta7050 · Cited by 163
Concin, N., Becker, K., Slade, N., Erster, S. H., Mueller-Holzner, E., Ulmer, H., Daxenbichler, G., Zeimet, A. G., Zeillinger, R., Marth, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1060 · Cited by 138
Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma
Soong, R., Powell, B., Elsaleh, H., Gnanasampanthan, G., Smith, D. R., Goh, H. S., Joseph, D. J., & Iacopetta, B. M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00285-9 · Cited by 122
Modulation of Gene Expression by Tumor-Derived p53 Mutants
Scian, M. J., Stagliano, K. E., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 117
Tumour suppressors: A developing role for p53?
Hall, P. A., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(97)70074-5 · Cited by 101
Self-citationThe results of colorectal cancer treatment by p53 status
Petersen, S., Thames, H. D., Nieder, C., Petersen, C., & Baumann, M. A. (2001) · Diseases of the Colon & Rectum · doi:10.1007/bf02234727 · Cited by 55
On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage
Lane, D. P., Midgley, C., Hupp, T. R., Lü, X., Vojtěšek, B., & Picksley, S. M. (1995) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1995.0013 · Cited by 51
Self-citationCooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
Gurova, K. V., Rokhlin, O. W., Budanov, A. V., Burdelya, L., Chumakov, P. M., Cohen, M. B., & Gudkov, A. V. (2003) · PubMed · Cited by 49
Klumb, C. E., Furtado, D. R., de Resende, L. M. M., Carriço, M. K., Coelho, A. M., de Meis, E., Maia, R. C., & Rumjanek, F. D. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00094.x · Cited by 28
Bazan, V., Migliavacca, M., Tubiolo, C., et al. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10088 · Cited by 23
Explaining heterogeneity in meta-analysis: a comparison of methods
Thompson, S. G., & Sharp, S. J. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991030)18:20
Cited by
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
The Chromosomal Instability Pathway in Colon Cancer
Pino, M. S., & Chung, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.065 · Cited by 932
Metadata
- Authors
- Munro, A. J., Lain, S., & Lane, D. P.
- Venue
- British Journal of Cancer
- Published
- 2005-01-25
- Volume
- 92
- Issue
- 3
- Pages
- 434-444
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1970221755
- Cited by
- 289
- References
- 33
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.